Abstracts tagged "anti-TNF therapy"

Abstract Number: 2862 • 2015 ACR/ARHP Annual Meeting
Is Anti-TNF Tapering Possible in Patients with Axial Spondyloarthritis? a Systematic Literature Review
Victoria Navarro-Compán¹, Chamaida Plasencia-Rodriguez², Eugenio De Miguel¹, Alejandro Balsa¹, Emilio Martín-Mola¹, Daniel Seoane-Mato³ and Juan D. Cañete⁴, ¹Rheumatology, University Hospital La Paz, Madrid, Spain, ²Rheumatology Department, La Paz University Hospital-Rheumatology Department, Madrid, Spain, ³Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ⁴Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain
Background/Purpose: Anti-TNF therapy is successful for achieving low disease activity (LDA) or clinical remission in patients with axial spondyloarhritis (axSpA). Nevertheless, this therapy has not…
Abstract Number: 604 • 2015 ACR/ARHP Annual Meeting
Calprotectin and TNF Antagonist Serum Trough Levels Identify Active Ultrasound Synovitis in Rheumatoid Arhritis and Psoriatic Arthritis Patients in Remission or Low Disease Activity
Jose Inciarte-Mundo¹, Julio Ramírez¹, Virginia Ruiz-Esquide¹, M. Victoria Hernández¹, Oscar Camacho¹, Sonia Cabrera-Villalba¹, Andrea Cuervo¹, Mariona Pascal², Jordi Yagüe², Juan D. Cañete¹ and Raimon Sanmarti¹, ¹Rheumatology Department, Hospital Clinic i Provincial, Barcelona, Spain, ²Immunology Department, Hospital Clinic i Provincial, Barcelona, Spain
Background/Purpose: An accurate assessment of disease activity is needed in Rheumatoid arthritis (RA) and Psoriatic Arthritis (PsA) patients in remission or low disease activity for…
Abstract Number: 1331 • 2015 ACR/ARHP Annual Meeting
Change in MRI in Patients with Spondyloarthritis Treated with Anti-TNF Agents : Systematic Review of the Literature
Gisèle KHOURY¹, BG Combe² and Cédric Lukas³, ¹Rheumatology, Hopital Lapeyronie, Montpellier, France, ²Lapeyronie, Montpellier, France, ³Hopital Lapeyronie, Montpellier, France
Background/Purpose: The follow-up of axial spondyloarthritis (SpA) remains difficult in clinical practice, mainly based on patient-reported outcomes, whereas objective parameters in disease monitoring are often…
Abstract Number: 2140 • 2015 ACR/ARHP Annual Meeting
Drug Specific Risk and Associated Factors for Vasculitis-like Events in Patients Exposed to Tumour Necrosis Factor-Î± Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Meghna Jani¹, William G Dixon², Lianne Kearsley-Fleet³, Ian N. Bruce^4,5, Hector Chinoy^6,7, Anne Barton^6,8, Mark Lunt⁹, Kath Watson³, Deborah P.M. Symmons¹, Kimme L. Hyrich³ and on behalf of the BSRBR-RA, ¹Centre for Musculoskeletal Research, University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ²Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁴Stopford Building, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ⁵Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ⁶Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ⁷NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ⁸NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom, ⁹Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom
Background/Purpose: The association between TNF inhibitors (TNFis) and vasculitis-like events, possibly secondary to induction of autoantibodies, has been well reported. However, the incidence, drug-specific differences…
Abstract Number: 2867 • 2015 ACR/ARHP Annual Meeting
Impact of Timely Versus Delayed Use of Anti-Tumor Necrosis Factor (TNF) Biologics in the Treatment of Psoriatic Arthritis: Results from a Modeling Study
Vibeke Strand¹, M. Elaine Husni², Zheng-Yi Zhou³, James Signorovitch³, Jenny Griffith⁴, Yichen Zhong³ and Arijit Ganguli⁴, ¹Stanford University, Palo Alto, CA, ²Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH, ³Analysis Group, Inc., Boston, MA, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: Progression of psoriatic arthritis (PsA) can lead to irreversible joint damage and functional impairment. TNF inhibitors (TNFi’s) have been shown to improve signs and…
Abstract Number: 616 • 2015 ACR/ARHP Annual Meeting
Risk Factors for the Exacerbation of Interstitial Lung Disease (ILD) after Administration of Biologic Dmards in RA Patients with Pre-Existing ILD
Tamao Nakashita¹, Akira Dibatake², Kotaro Matsumoto³, Yoto Hamada⁴ and Shinji Motojima⁵, ¹Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa-city, Japan, ²Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa, Japan, ³Department of Rheumatology and Allergy, Kameda Medical Center, kamogawa, Japan, ⁴Department of Rheumatology and Allergy, Kameda Medical Center, Kamogwa, Japan, ⁵Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan
Background/Purpose: Interstitial lung disease (ILD) associated with RA is a big concern particularly in Japanese patients evidenced by the reports that the cause of death…
Abstract Number: 1351 • 2015 ACR/ARHP Annual Meeting
Long-Term Efficacy of Latent Tuberculosis Infection Screening in Juvenile Idiopathic Arthritis Patients Prior to Anti-TNF Treatment in an Endemic Area
Juliana Brunelli¹, Karina Bonfiglioli^2,3, Clovis A Silva⁴, Katia T. Kozu⁵, Cláudia Goldenstein-Schainberg⁶, Eloisa Bonfá¹ and Nadia E Aikawa⁴, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ³Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Pediatric Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁵Pediatrics, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁶Clínica Médica, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil
Background/Purpose: We have demonstrated previously that latent tuberculosis infection (LTBI) screening is effective in adult rheumatoid arthritis (RA) patients prior to anti-TNF treatment. One study…
Abstract Number: 2149 • 2015 ACR/ARHP Annual Meeting
Dose Reduction Compared with Standard Dosing for Maintenance of Remission in Patients with Spondyloarthropathies and Clinical Remission with Anti-TNF: A Randomised Real-Life Trial
Jorge Gratacos-Masmitja¹, Caridad Pontes², Ferran Torres³, Xavier Juanola⁴, Antoni Vallano⁵, TC Salman-Monte⁶, Francisco J. Blanco⁷, Agusti Sellas-Fernandez⁸, Raimon Sanmarti⁹, Gonzalo Calvo¹⁰, Teresa Clavaguera¹¹, Raul Veroz Gonzalez¹², Juan Carlos Torre Alonso¹³, Jesus Sanz¹⁴, Cristina Avendaño¹⁵, Carlos Rodriguez-Lozano¹⁶, Luis Francisco Linares¹⁷, Ana Urruticoechea¹⁸, Eduardo Collantes-Estévez¹⁹, Rosa Morla Novell²⁰, Delia Reina²¹, Eduardo Cuende²², Pedro Zarco²³, Cruz Fernández- Espartero²⁴, Rosario Garcia-Vicuña²⁵, Carlos Alberto Montilla Morales²⁶, Eugenio De Miguel²⁷, Roser Vives² and Mireia Moreno²⁸, ¹Rheumatology, Hospital de Sabadell - Institut Universitari Parc Taulí, Sabadell, Spain, ²Clinical Pharmacology, Hospital de Sabadell - Institut Universitari Parc Taulí, Sabadell, Spain, ³Biostatistics and Data Management Platform, IDIBAPS - Hospital Clínic de Barcelona, Barcelona, Spain, ⁴Rheumatology, Hospital Universitari de Bellvitge, Barcelona, Spain, ⁵Hospital de Bellvitge, Barcelona, Spain, ⁶Rheumatology, Hospital del Mar/Parc de Salut Mar, Barcelona, Spain, ⁷Osteoarticular and Aging Research Lab. Proteomics Unit - Associated Node to ProteoRed, Rheumatology Division, Proteomics Group-ProteoRed/ISCIII, INIBIC-CHUAC, A Coruña, Spain, ⁸Rheumatology, Hospital Universitario Valle Hebron, Barcelona, Spain, ⁹Rheumatology Department, Hospital Clinic i Provincial, Barcelona, Spain, ¹⁰Hospital Clínic de Barcelona, Barcelona, Spain, ¹¹CapiCAT group (Nailfold Capillaroscopy group from the Catalan Society for Rheumatology)., Catalonia, Spain, ¹²Hospital de Mérida, Mérida, Spain, ¹³Perez de la Sala 33, 3oA., H. Monte Naranco, Oviedo, Spain, ¹⁴Rheumatology, Hospital Puerta de Hierro Majadahonda, Madrid, Spain, ¹⁵Hospital Puerta de Hierro - Majadahonda, Madrid, Spain, ¹⁶Hospital Ubniversitario Dr. Negrin, Las Palmas de Gran Canaria, Spain, ¹⁷Rheumatology, Hospital Virgen de la Arrixaca, Murcia, Spain, ¹⁸Hospital Can Misses, Ibiza, Spain, ¹⁹IMIBIC-Reina Sofia University Hospital, Rheumatology Unit, Cordoba, Spain, ²⁰Rheumatology UNit., Hospital Sta Tecla, Tarragona, Spain, ²¹Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ²²University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcalá de Henares, Madrid, Spain, ²³H Fundación Alcorcón, Alcorcón, Spain, ²⁴Rheumatology, Hospital La Zarzuela, Madrid, Spain, ²⁵Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ²⁶Rheumatology, Hospital Universitario de Salamanca, Salamanca, Spain, ²⁷Rheumatology, University Hospital La Paz, Madrid, Spain, ²⁸Hospital de Sabadell - Institut Universitari Parc Taulí, Sabadell, Spain
Background/Purpose: Tumour Necrosis Factor alpha inhibitors (TNFi) have proven to be effective in the treatment of with spondyloarthropaties. There is rationale to support that in…
Abstract Number: 2869 • 2015 ACR/ARHP Annual Meeting
Impact of Methotrexate on the Real-World Effectiveness of Golimumab in Psoriatic Arthritis
Louis Bessette¹, Proton Rahman², Denis Choquette³, John Kelsall⁴, Maqbool Sheriff⁵, Emmanouil Rampakakis⁶, Eliofotisti Psaradellis⁷, Allen J Lehman⁸, Karina Maslova⁸, Francois Nantel^9,10, Brendan Osborne¹¹ and Cathy Tkaczyk¹¹, ¹Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ²Medicine, Memorial University, St John's, NF, Canada, ³Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ⁴Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁵Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁶JSS Medical Research, St-Laurent, QC, Canada, ⁷JSS Medical Research, Montreal, QC, Canada, ⁸Janssen Inc., Toronto, ON, Canada, ⁹Schering Plough Canada Inc., Janssen Inc., Kirkland, QC, QC, Canada, ¹⁰19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: : Previous controlled clinical trials have shown that concurrent methotrexate (MTX) therapy may enhance the efficacy of anti-TNF agents. However, real-world data on the…
Abstract Number: 618 • 2015 ACR/ARHP Annual Meeting
The Multi-Biomarker Disease Activity Score in Methotrexate Incomplete Responders Predicts Clinical Responses to Non-Biological Versus Biological Therapy in Early RA
Karen Hambardzumyan¹, Rebecca J. Bolce², Saedis Saevarsdottir³, Kristina Forslind^4,5, Johan A Karlsson⁶ and Ronald F. van Vollenhoven¹, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³Department of Medicine, Rheumatology Unit, The Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden, ⁴Department of Medicine, Helsingborgs Lasarett, Section of Rheumatology, Helsingborg, Sweden, ⁵Departments of Rheumatology, Helsingborgs Hospital and University of Lund, Helsingborg and Lund, Sweden, ⁶Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
Background/Purpose: The Swedish Farmacotherapy (SWEFOT) trial and other trials in rheumatoid arthritis (RA) demonstrated that in MTX incomplete responder patients (MTX-IR) the addition of anti-TNF…
Abstract Number: 1520 • 2015 ACR/ARHP Annual Meeting
Safety, Clinical and Immunologic Effectiveness of the Live Zoster Vaccine Administered to Patients Receiving Anti-TNF Biologics
Jeffrey R. Curtis^1,2, Anita Turner³, Corretta Thomas⁴, Stacey Cofield⁴, Randall Parks⁵, Jennifer H. Ku⁶, Ilhem Messaoudi- Powers⁷, Keith Wanzeck¹ and Kevin L. Winthrop⁸, ¹University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama-Birmingham, Birmingham, AL, ³Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴School of Public Health, University of Alabama at Birmingham, Birmingham, AL, ⁵Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Casey Eye Institute, Oregon Health & Science Univ, Portland, OR, ⁷Oregon Health and Sciences University, Portland, OR, ⁸Oregon Health & Science University, Portland, OR
Background/Purpose: The live herpes zoster vaccine (ZV) has been shown to be safe and effective in large randomized controlled trials of older adults. It is…
Abstract Number: 2603 • 2015 ACR/ARHP Annual Meeting
What Is the Variability of HAQ over Time in Patients with Rheumatoid Arthritis Treated with Anti-TNF?
Regan Arendse¹, Boulos Haraoui², Denis Choquette³, John Kelsall⁴, Philip Baer⁵, Dalton Sholter⁶, William G. Bensen⁷, Mary J. Bell⁸, Michelle Teo⁹, Emmanouil Rampakakis¹⁰, Eliofotisti Psaradellis¹¹, Brendan Osborne¹², Cathy Tkaczyk¹², Karina Maslova¹³, Francois Nantel¹⁴ and Allen J Lehman¹³, ¹University of Saskatchewan, Saskatoon, SK, Canada, ²Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ³Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ⁴Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁵Section on Rheumatology, Ontario Medical Association/Journal of the Canadian Rheumatology Association, Toronto, ON, Canada, ⁶Rheumatology Associates, Edmonton, AB, Canada, ⁷St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁸Rheum Div, Sunnybrook Health Sciences Centre/University of Toronto, Toronto, ON, Canada, ⁹Rheumatology, Penticton Regional Hospital, Penticton, BC, Canada, ¹⁰JSS Medical Research, St-Laurent, QC, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Janssen Inc., Toronto, ON, Canada, ¹⁴19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose : The Health Assessment Questionnaire (HAQ) remains the gold standard for measuring patient-reported functional status in rheumatoid arthritis (RA) and is included among the…
Abstract Number: 2870 • 2015 ACR/ARHP Annual Meeting
Predictors of Early Minimal Disease Activity in Psa Patients Treated with Anti-TNF in a Real-World Registry
Michel Zummer¹, Proton Rahman², Regan Arendse³, Michael Starr⁴, John Kelsall⁵, J Antonio Avina-Zubieta⁶, Philip Baer⁷, Dalton Sholter⁸, Michelle Teo⁹, Emmanouil Rampakakis¹⁰, Eliofotisti Psaradellis¹¹, Brendan Osborne¹², Karina Maslova¹³, Francois Nantel¹⁴, Allen J Lehman¹³ and Cathy Tkaczyk¹², ¹Rheumatology, Hôpital Maisonneuve-Rosemont and University of Montreal, Montreal, QC, Canada, ²Medicine, Memorial University, St John's, NF, Canada, ³University of Saskatchewan, Saskatoon, SK, Canada, ⁴Rheumatology, McGill University, Montreal, QC, Canada, ⁵Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁶Arthritis Research Canada / University of British Columbia, Vancouver, BC, Canada, ⁷Section on Rheumatology, Ontario Medical Association/Journal of the Canadian Rheumatology Association, Toronto, ON, Canada, ⁸Rheumatology Associates, Edmonton, AB, Canada, ⁹Rheumatology, Penticton Regional Hospital, Penticton, BC, Canada, ¹⁰JSS Medical Research, St-Laurent, QC, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Janssen Inc., Toronto, ON, Canada, ¹⁴19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Early achievement of minimal disease activity (MDA) is recommended as a valid treat-to-target approach in psoriatic arthritis (PsA). The purpose of the current analysis…
Abstract Number: 653 • 2015 ACR/ARHP Annual Meeting
Clinical Responses and Improvements in Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol
Désirée van der Heijde¹, Juergen Braun², Martin Rudwaleit³, Oana Purcaru⁴ and Arthur Kavanaugh⁵, ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Klinikum Bielefeld, Bielefeld, Germany, ⁴UCB Pharma, Brussels, Belgium, ⁵University of California San Diego, La Jolla, CA
Background/Purpose: Axial spondyloarthritis (axSpA) includes ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA).1 AS significantly affects patient (pt) workplace productivity in both performance and disease-related absenteeism.2…
Abstract Number: 1636 • 2015 ACR/ARHP Annual Meeting
Clinical Benefit of 1-Year Certolizumab Pegol Treatment in MTX-Naïve, Early Rheumatoid Arthritis Patients Is Maintained after Discontinuation up to 1 Year
Tatsuya Atsumi¹, Kazuhiko Yamamoto², Tsutomu Takeuchi³, Hisashi Yamanaka⁴, Naoki Ishiguro⁵, Yoshiya Tanaka⁶, Katsumi Eguchi⁷, Akira Watanabe⁸, Hideki Origasa⁹, Toshiharu Shoji¹⁰, Osamu Togo¹¹, Toshiyuki Okada¹², Désirée van der Heijde¹³, Nobuyuki Miyasaka¹⁴ and Takao Koike¹⁵, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³Keio University School of Medicine, Tokyo, Japan, ⁴Tokyo Women's Medical University, Tokyo, Japan, ⁵Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan, ⁶The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁷Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ⁸Tohoku University, Sendai, Japan, ⁹Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Toyama, Japan, ¹⁰Department of Clinical Research and Development, Otsuka Pharmaceutical Co., Ltd, Shinagawa-ku, Tokyo, Japan, ¹¹Biometrics Group, UCB Pharma, Tokyo, Japan, ¹²Astellas Pharma Inc., Japan, Tokyo, Japan, ¹³University Hospital, Maastricht, Netherlands, ¹⁴Tokyo Medical and Dental University, Tokyo, Japan, ¹⁵Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Efficacy and safety of certolizumab pegol (CZP) treatment in combination with optimized-dose MTX in Japanese MTX-naïve early rheumatoid arthritis (RA) patients (pts) with poor…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].